Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M MacDonald

Showing results (101-110 of 159) with videos related to

Pageof 16
Sort By:
Trials|November 18, 2021
Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertensionAmy Rogers, Angela Flynn, Isla S Mackenzie, et al.
BMC Cardiovascular Disorders|May 11, 2007
Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) studyHari K Parthasarathy, Khamis Alhashmi, Alex D McMahon, et al.
BMJ Open|September 10, 2016
Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART studyIsla S Mackenzie, Ian Ford, Andrew Walker, et al.
BMJ Open|June 1, 2022
Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety studyAmy Rogers, Evelien Rooke, Steve Morant, et al.
Journal of the American College of Cardiology|August 28, 2012
Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart diseaseM Adnan Nadir, Sushma Rekhraj, Li Wei, et al.
American Heart Journal|September 20, 2005
Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger, William B White, Luis-Miguel Ruilope, et al.
American Journal of Hypertension|October 21, 2020
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)Linsay McCallum, Katriona Brooksbank, Alex McConnachie, et al.
Journal of Hypertension|July 4, 2019
Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertensionChristopher R Gingles, Ruth Symon, Stephen J Gandy, et al.
Seminars in Arthritis and Rheumatism|February 25, 2014
Up-titration of allopurinol in patients with goutClaudine G Jennings, Isla S Mackenzie, Rob Flynn, et al.
Pharmacoepidemiology and Drug Safety|December 5, 2002
The safety of drugs for OTC use: what evidence is required for an NSAID switch?Thomas M MacDonald, Keith Beard, Rudolf Bruppacher, et al.
Pageof 16

Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Trials|November 18, 2021
Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertensionAmy Rogers, Angela Flynn, Isla S Mackenzie, et al.
BMC Cardiovascular Disorders|May 11, 2007
Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) studyHari K Parthasarathy, Khamis Alhashmi, Alex D McMahon, et al.
BMJ Open|September 10, 2016
Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART studyIsla S Mackenzie, Ian Ford, Andrew Walker, et al.
BMJ Open|June 1, 2022
Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety studyAmy Rogers, Evelien Rooke, Steve Morant, et al.
Journal of the American College of Cardiology|August 28, 2012
Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart diseaseM Adnan Nadir, Sushma Rekhraj, Li Wei, et al.
American Heart Journal|September 20, 2005
Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger, William B White, Luis-Miguel Ruilope, et al.
American Journal of Hypertension|October 21, 2020
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)Linsay McCallum, Katriona Brooksbank, Alex McConnachie, et al.
Journal of Hypertension|July 4, 2019
Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertensionChristopher R Gingles, Ruth Symon, Stephen J Gandy, et al.
Seminars in Arthritis and Rheumatism|February 25, 2014
Up-titration of allopurinol in patients with goutClaudine G Jennings, Isla S Mackenzie, Rob Flynn, et al.
Pharmacoepidemiology and Drug Safety|December 5, 2002
The safety of drugs for OTC use: what evidence is required for an NSAID switch?Thomas M MacDonald, Keith Beard, Rudolf Bruppacher, et al.
Pageof 16